Kassa Eyuel, Enawgaw Bamlaku, Gelaw Aschalew, Gelaw Baye
Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences (CMHS), University of Gondar (UOG), Gondar, Ethiopia.
Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
BMC Hematol. 2016 Jan 8;16:1. doi: 10.1186/s12878-015-0037-1. eCollection 2016.
Tuberculosis (TB) treatment may present significant hematological disorder and some anti-TB drugs also have serious side effects. Although many other diseases may be reflected by the blood and its constituents, the abnormalities of red cells, white cells, platelets, and clotting factors are considered to be primary hematologic disorder as a result of tuberculosis treatment. The aim of this study was to determine hematological profiles of TB patients before and after intensive phase treatment.
The aim of this study was to determine hematological profiles of TB patients before and after intensive phase treatment.
Smear positive new TB patients were recruited successively and socio-demographic characteristics were collected using pre-tested questionnaire. About 5 ml of venous blood was collected from each patient and the hematological profiles were determined using Mindry BC 3000 plus automated hematology analyzer.
The hematological profiles of TB patients showed statistically significant difference in hematocrit (38.5 % versus 35.7 %), hemoglobin (12.7 g/lversus11.8 g/l) and platelet (268 × 10(3)/μlversus239 × 10(3)/μl) values of patients before initiation of treatment and after completion of the intensive phase of tuberculosis treatment, respectively (P < 0.05). The red cell distribution width (RDW) of treatment naïve TB patients was by far lower (17.6 ± 7.09 %) than the corresponding RDW (31.9 ± 5.19 %) of intensive phase treatment completed patients. Among TB patients that had high platelet distribution width (PDW) (n = 11) before initiation of TB treatment, 10 demonstrated lower PDW values after completion of the intensive phase. There was no significant difference on total white blood cell count among TB patients before and after completion of the 2 month treatment.
The levels of hemoglobin, hematocrit and platelet count of the TB patients were significantly lowered after completion of the intensive phase of TB treatment. Significant variation of the RDW and PDW were also observed among treatment naïve and treatment completed patients. Hematological abnormalities resulted from TB treatment should be assessed continuously throughout the course of tuberculosis therapy.
结核病治疗可能会出现显著的血液系统紊乱,一些抗结核药物也有严重的副作用。尽管许多其他疾病可能通过血液及其成分反映出来,但红细胞、白细胞、血小板和凝血因子的异常被认为是结核病治疗导致的原发性血液系统紊乱。本研究的目的是确定结核病患者强化期治疗前后的血液学特征。
本研究的目的是确定结核病患者强化期治疗前后的血液学特征。
连续招募涂片阳性的新发结核病患者,并使用预先测试的问卷收集社会人口学特征。从每位患者采集约5毫升静脉血,使用Mindry BC 3000 plus全自动血液分析仪测定血液学特征。
结核病患者的血液学特征显示,在开始治疗前和完成结核病强化期治疗后,患者的血细胞比容(38.5%对35.7%)、血红蛋白(12.7 g/l对11.8 g/l)和血小板(268×10³/μl对239×10³/μl)值存在统计学显著差异(P<0.05)。未接受过治疗的结核病患者的红细胞分布宽度(RDW)远低于完成强化期治疗患者的相应RDW(31.9±5.19%)(17.6±7.09%)。在开始结核病治疗前血小板分布宽度(PDW)较高(n = 11)的结核病患者中,10例在完成强化期治疗后PDW值降低。在完成2个月治疗前后,结核病患者的白细胞总数无显著差异。
结核病患者在完成强化期治疗后,血红蛋白、血细胞比容和血小板计数水平显著降低。在未接受过治疗和完成治疗的患者中也观察到RDW和PDW的显著变化。在结核病治疗过程中应持续评估结核病治疗导致的血液学异常。